Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors - Concepedia

Concepedia

Publication | Open Access

Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors

DOI Full Paper Access

68

Citations

26

References

2021

Year

James Spicer, Aurélien Marabelle, Jean‐François Baurain, Nina Louise Jebsen, Dag Erik Jøssang, Ahmad Awada, Rebecca Kristeleit, Delphine Loirat, George Lazaridis, Christiane Jungels,

Clinical Cancer Research

Abstract

LTX-315 has an acceptable safety profile, is clinically active, induces changes in the tumor microenvironment and contributes to immune-mediated anticancer activity.

References

	Year	Citations

Page 1